A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
ORGANIZATION
JPA Urges MHLW to Allow Access to List of Registered Pharmacies Carrying Lagevrio
Pharmacies in Japan are calling for access to the list of registered pharmacies that carry the oral COVID-19 treatment Lagevrio (molnupiravir). The Japan Pharmaceutical Association (JPA) said that it has made this request to the health minister. The call was…
To read the full story
ORGANIZATION
- JPMA Embarking on Holistic Social Security Debate, Health Coverage Review: Chief
January 21, 2022
- CEA Process to Be Improved, but Operational Issues Remain: PhRMA/EFPIA
January 20, 2022
- JGA Chief Pledges to Restore Trust in Generics in 2022
January 14, 2022
- Osamu Kunii of Global Fund to Become New GHIT Fund CEO
January 13, 2022
- FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…